Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $7.4B. The Maz Rating grades it against the other companies in its sector.
Amneal Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $21.12, Amneal Pharmaceuticals, Inc. trades at 48.7x trailing earnings, 2.3x sales and 13.2x book value, with an EV/EBITDA of 15.7. Over the last twelve months it generated about $3.2B of revenue and $151M of net income. It runs a gross margin of 40.2%, an operating margin of 15.6% and a net margin of 4.6%. It shows return on equity of 131.7%, return on invested capital of 10.8% and a free cash flow yield of 0.6%. On the balance sheet: a debt-to-equity ratio of 6.18 and a current ratio of 1.87. Over the past 52 weeks the share price ranged from $11.39 to $22.07, with a beta of 1.21.
Amneal Pharmaceuticals, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 12 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Amneal Pharmaceuticals, Inc. (AMRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 49.9% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.52% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 49.9% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.52% / 33% · Receivables / Mkt Cap (36m) 16.3% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 49.9% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.52% / 33.33% · Receivables / Mkt Cap (24m) 16.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 67.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 4.88% / 33.33% · Receivables / Avg Assets (4Q) 23.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 59.2% / 33.33% · (Cash+ST Inv) / Total Assets 2.99% / 33.33% · (Cash+Recv) / Total Assets 22.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Amneal Pharmaceuticals, Inc. (AMRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Amneal Pharmaceuticals, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
Amneal Pharmaceuticals, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.